Black Diamond Therapeutics (NASDAQ:BDTX) Price Target Increased to $15.00 by Analysts at Piper Sandler

Black Diamond Therapeutics (NASDAQ:BDTX) had its price objective boosted by Piper Sandler from $12.00 to $15.00 in a research note released on Monday morning, Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

Several other analysts also recently issued reports on BDTX. HC Wainwright reissued a buy rating and set a $11.00 target price on shares of Black Diamond Therapeutics in a research note on Wednesday, September 18th. Wedbush restated an outperform rating and set a $16.00 target price on shares of Black Diamond Therapeutics in a research report on Tuesday, September 10th. Finally, Raymond James began coverage on shares of Black Diamond Therapeutics in a report on Wednesday, July 31st. They issued an outperform rating and a $20.00 price target on the stock.

Black Diamond Therapeutics Price Performance

Shares of BDTX stock opened at $4.20 on Monday. Black Diamond Therapeutics has a 1 year low of $1.62 and a 1 year high of $7.66. The firm has a fifty day moving average price of $5.60 and a 200-day moving average price of $5.36. The company has a market cap of $237.34 million, a price-to-earnings ratio of -2.53 and a beta of 2.49.

Black Diamond Therapeutics (NASDAQ:BDTX) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.03. Equities research analysts expect that Black Diamond Therapeutics will post -1.4 EPS for the current year.

Institutional Investors Weigh In On Black Diamond Therapeutics

Large investors have recently bought and sold shares of the business. Ally Bridge Group NY LLC bought a new stake in shares of Black Diamond Therapeutics in the 2nd quarter valued at approximately $3,891,000. Affinity Asset Advisors LLC purchased a new position in shares of Black Diamond Therapeutics during the 2nd quarter worth about $3,029,000. Bellevue Group AG grew its holdings in Black Diamond Therapeutics by 4.9% during the 4th quarter. Bellevue Group AG now owns 8,535,839 shares of the company’s stock valued at $23,986,000 after purchasing an additional 400,000 shares during the last quarter. TD Asset Management Inc lifted its stake in Black Diamond Therapeutics by 275.9% in the second quarter. TD Asset Management Inc now owns 266,312 shares of the company’s stock worth $1,241,000 after purchasing an additional 195,464 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in shares of Black Diamond Therapeutics during the second quarter valued at approximately $508,000. Institutional investors own 95.47% of the company’s stock.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.